REGN peers and competitors
Regeneron Pharmaceuticals, Inc. · end-of-day data as of Oct 16, 2026
Regeneron Pharmaceuticals, Inc.
$790.74+20.7%
Buy · 29 analystsPT $859.53 +8.7%
REGN’s peers by industry and size include Vertex Pharmaceuticals (VRTX), HCA Healthcare (HCA) and Elevance Health (ELV). Among these 12 companies REGN ranks 5th by market cap ($81.41B); its P/E of 19.6 compares with a median of 22.2 for its peers.
Peers by industry and size
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $499.74 | -1.8% | -10.4% | +14.0% | 29.1 | $127B | |
| 2 |  | $458.84 | -2.1% | -15.4% | +2.1% | 15.4 | $99.34B | |
| 3 |  | $428.26 | 0.0% | 0.0% | +1.9% | 19.0 | $92.88B | |
| 4 |  | $218.01 | -7.8% | -7.8% | -25.0% | — | $87.04B | |
| 5 | | $790.74 | -0.7% | -7.2% | +8.7% | 19.6 | $81.41B | |
| 6 |  | $302.30 | +1.2% | -0.2% | +10.9% | 12.5 | $79.88B | |
| 7 |  | $340.92 | -0.1% | -8.5% | +6.8% | 25.3 | $65.06B | |
| 8 |  | $44.39 | +0.6% | -57.7% | +50.1% | 18.0 | $64.33B | |
| 9 |  | $254.06 | +0.1% | 0.0% | +4.5% | 35.1 | $58.83B | |
| 10 |  | $231.83 | -0.9% | -52.8% | +61.5% | 39.2 | $31.02B | |
| 11 |  | $113.07 | -0.2% | -13.0% | +13.6% | 14.4 | $22.92B | |
| 12 |  | $72.57 | +0.1% | -0.1% | -7.0% | 62.6 | $11.38B |
Data as of Oct 16, 2026 close.